In a more recent study published in 2011 [69] it was shown that HER2 testing in GC could be performed using standard breast cancer procedures and the American Society of Clinical Oncology/College of American Pathologists scoring criteria, while a group from Korea concluded that a GC-specific scoring system should be used [70]. The gene discussed is ERBB2; the disease is breast cancer.